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Lung cancer (LC) is often diagnosed at an advanced stage, 
when therapeutic options are limited; patients would 
greatly benefit from an early diagnosis. A 20% reduction 
of LC mortality has been shown in high risk individuals 
undergoing chest computed tomography screening for 
early diagnosis of LC. However, high radiation exposure, 
cost/benefit ratio and false positive rates still represent 
concerns about large scale use of this screening 
technique. Minimally invasive methods, allowing 
identification of subjects with early LC risk are urgently 
needed. MicroRNAs (miRNAs) are short, single-stranded, 
non-coding RNAs detectable in biological fluids. Levels of 
specific, circulating cell-free miRNAs have been shown to 
correlate with disease states, including LC. This suggested 
their potential application as circulating biomarkers of LC. 
We hypothesized that the serum level of specific miRNAs 
could discriminate between subjects with and without LC. 
Based on a systematic review of the literature, we 
selected a panel of ten miRNAs (miR-15b-5p, miR-21-5p, 
miR-27b-3p, miR-126-3p, miR-155-5p, miR-210-3p, miR-
221-3p, miR-320a, miR-486-5p, let-7a-5p) and tested if 
these could discriminate between normal subjects and LC 
patients. 
 
First, we compared the performance of three methods, 
namely relative qPCR, absolute qPCR and droplet digital 
PCR (ddPCR), in accurately measuring the levels of 
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circulating miRNAs. We found that although all three 
methods are suitable to this aim, ddPCR provided greater 
precision and higher throughput of analysis than the other 
qPCR methods, at a similar cost-per-sample. Moreover, 
ddPCR does not rely on the use of reference genes or 
external calibrators.  
 
We then started to characterize the applicability of our 
miRNA panel to the clinic. Based on sensitivity to 
hemolysis, we excluded two miRNAs (miR-486 and miR-
155). The remaining eight miRNAs were measured by 
ddPCR in 85 patients with early LC (stage I and II) and 83 
controls. Four out of the eight analyzed miRNAs showed 
significant differences in serum levels between LC patients 
and controls (let-7a, miR-210, miR-320a: p<0.0001; miR-
221: p=0.0119). For each of these four miRNAs, the 
Receiver Operating Characteristic (ROC) curve was 
constructed and the Area Under the Curve (AUC) 
calculated. AUCs showed fair accuracy in identifying early 
LC cases (about 0.7 for each miRNA). 
 
In conclusion, ddPCR proved to be a robust method for 
absolute quantification of miRNA serum levels in LC 
patients. For four of our miRNAs, putative biomarkers of 
LC, the AUC showed fair accuracy in identifying early LC 
cases. Taken together, a combination of these, and 
possibly additional miRNAs, may aid to identify subjects 
	 8	






















































Lung cancer epidemiology 
 
Lung cancer is the leading cause of cancer related deaths 
worldwide [Jemal et al, 2011] with about 1.8 million new 
cases in 2012 [Globocan, 2012]. In Italy, more than 
38,000 new lung cancers are annually diagnosed 
[AIRTUM, 2015], that heavily impact on the health-care 
system. The survival rate of lung cancer remains low (10-
15% at 5 years from diagnosis), despite recent advances 
in management and treatment of the disease; advanced 
stage at diagnosis in about ¾ of lung cancer cases 
prevents effective treatment and long-term survival. 
Incidence and mortality are higher in men than in women, 
although in recent years this gap is gradually closing due 
to increasing diffusion of smoking habit among women. It 
is well known that lung cancer incidence parallels the use 
of tobacco, as cigarette smoking is the most important 
risk factor for lung cancer. Generally, the diseases is 
clinically diagnosed in patients 50 to 75 years of age, with 
over ⅓ of cases diagnosed in people over 70 years old. 
Diagnosis of lung cancer sometimes occurs incidentally, 
with sputum cytology or chest-X-rays carried out for other 
reasons. However, these exams, when used for lung 
cancer screening purposes, have demonstrated limited 
sensitivity and their use has not produced a marked 
reduction in mortality [Flehinger and Melamed, 1994; 
Dominioni et al, 2013]. 
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On the other hand, several studies, conducted in high-risk 
patients (older than 50 years and heavy smokers), using 
spiral computerized axial tomography (CAT), have 
reported promising results in identifying lung cancer in 
asymptomatic patients, when the tumor is small in size 
and at an early stage: 20% reduction in death risk [The 
National Lung Screening Trial Research Team, 2011]. 
Nevertheless, CAT scans present disadvantages, including 
exposure to radiation, high rate of false positive findings 
and risk of over-diagnosis. Currently the cost/benefit ratio 
of CAT screening for lung cancer is debated, therefore the 
routine use of CAT screening is still an open issue [Strauss 
and Dominioni, 2013]. 
Novel, sensitive and non-invasive methods for screening 
of lung cancer in high risk individuals are greatly needed, 
so that lung cancer may be identified at an early stage, 
when the chances of cure are higher. 
 
 
Lung cancer etiology 
 
Exogenous risk factors 
Development of lung cancer results from synergy between 
individual factors and environmental exposures. Lung 
cancer has a primary etiologic factor, tobacco smoke, the 
major toxic agents of which are nicotine, carbon 
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monoxide, hydrogen cyanide, nitrogen oxides, volatile 
aldehydes, alkenes, and aromatic hydrocarbons 
[Hoffmann et al, 2001]. The risk of developing lung cancer 
is proportional to the duration of the habit and the 
average number of cigarettes smoked per day.  The latter 
two parameters are combined to give a numerical value 
called “pack years” that considers lifetime exposure to 
tobacco smoking.  
Conversely, smoking cessation may result in a reduced 
risk of cancer, which, however, remains relevant for 10-15 
years after smoking cessation and still remains higher 
than in non-smokers, even after 40 years [Alberg et al, 
2003]. After 10 years of abstinence, the risk of lung 
cancer is 30% to 50% lower than that of continuing 
smokers [Patterson et al, 2008]. This is explained by 
cellular changes in gene expression, such as the 
expression of growth factors, induced by prolonged 
inflammatory smoke stimulus, that determine an 
hyperproliferation of respiratory epithelium. Smoking 
cessation will not lead to reversion of existing cellular 
genetic modifications, such as DNA mutations induced by 
exposure to mutagens contained in tobacco smoke, but it 
may delay the development of cancer by avoiding the 
accumulation of further mutations and epigenetic changes 
[Fraser et al, 2011]. 
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Endogenous risk factors 
Endogenous factors that play a role in the etiology of lung 
cancer are genetic factors [Chen et al, 2014] and a 
previous history of lung disease [Alberg and Samet, 
2003]. 
Common genes associated with lung cancer susceptibility 
are TP53, EGFR, and the RAS family. TP53 is the tumor-
suppressor gene most frequently affected by mutations in 
human cancers. Its protein product is a transcription 
factor that has been named “guardian of the genome”, 
due to its ability to respond to various types of stress 
(DNA damage, ROS, hypoxia, etc), by inducing cell cycle 
arrest, apoptosis and DNA repair, thus preventing 
accumulation of DNA mutations and eliminating cells with 
a heavily damaged genome [Williams and Schumacher, 
2016; Chen, 2016]. 
Prevalence of p53 mutations increases from in situ lesions 
to metastatic carcinomas [Travis et al, 2015]. 
EGFR is a transmembrane growth factor receptor with 
tyrosine kinase (TK) activity. Intracellular signaling by 
EGFR is mediated through different signal transduction 
pathways, i.e. the RAS-RAF-MEK-MAPK pathway, the 
PI3K-PTEN-AKT pathway and the STAT pathway. 
Downstream, EGFR signaling leads to increased 
proliferation, angiogenesis, metastasis and decreased 
apoptosis. Mutations in the TK domain result in 
constitutive and oncogenic activation of EGFR signaling 
	 14	
[da Cunha Santos et al, 2011] and are present in about 
10% of NSCLC patients have EGFR mutations [Paez et al, 
2004; Lynch et al, 2004]. 
Mutations in the RAS gene family lead to constitutive 
activation of the MAPK signal transduction pathway. This 
in turn promotes cell motility and, consequently, 
invasiveness and metastatic potential [Campbell and Der, 
2014]. Approximately 15-25% of patients with 
adenocarcinoma have tumor KRAS mutations in their 
tumors, whereas this lesion is uncommon in squamous 
cell carcinoma [Chen et al 2014; Brose et al 2002]. 
 
A positive past medical history of pulmonary disorders, 
such as diffuse interstitial pulmonary fibrosis and chronic 
obstructive pulmonary disease (COPD), is associated with 
an increased susceptibility to lung cancer. In the case of 
diffuse interstitial pulmonary fibrosis, the increased risk of 
lung cancer development is linked to the higher 
proliferative activity of metaplastic tissue and focal 
hyperplasia present in association with the areas of 
fibrosis. Instead, the cause for the increased risk for 
cancer in COPD is likely due to the fact that COPD and 
lung cancer share a common etiological factor, chronic 
oxidative stress, suffered by airway walls during the 
course of chronic pulmonary disease [Spiro, 1997; Alberg 
and Samet, 2003; Fraser et al, 2011]. 
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Lung cancer subtypes 
 
Lung cancer is a heterogeneous disease both at the 
histological and at the molecular level. Based on 
morphology, two main types of lung cancer are 
identifiable: small cell lung cancer (SCLC) and non-small 
cell lung cancer (NSCLC) [Travis et al, 2015]: NSCLC 
comprises more than 80% of cases [Davidson et al, 2013; 
Langer et al, 2010; Chen et al, 2014] and it can be further 
subdivided into three subtypes: adenocarcinoma (ADC) 
(50%), squamous cell carcinoma (SQCC) (40%) and large 
cell carcinoma (LCC) (10%). 
 
Small Cell Lung Cancer 
SCLC consists of small cells with ill-defined cell borders, 
scant cytoplasm, finely granular nuclear chromatin and 
absent or inconspicuous nucleoli. The cells are round, oval 
or spindle-shaped. Nuclear molding is prominent. Necrosis 
is typically extensive and the mitotic count is high [Travis 
et al, 2015]. At the time of diagnosis, approximately 30% 
of patients with SCLC will have tumors confined to the 
mediastinum or the supraclavicular lymph nodes and they 
are designated as having limited-stage disease. Patients 
with tumors that have spread beyond the supraclavicular 
areas are said to have extensive-stage disease. SCLC is 
more responsive to chemotherapy and radiotherapy than 
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other types of lung cancer; however cure is difficult 
because SCLC is often disseminated by the time of 
diagnosis [National Cancer Institute: PDQ® Small Cell 
Lung Cancer Treatment]. 
 
Non-Small Cell Lung Cancer 
NSCLC is any type of epithelial lung cancer other than 
SCLC. It is a heterogeneous group of diseases that 
comprises three major histological subtypes: ADC, SQCC 
and LCC. 
ADC is a malignant epithelial tumor with glandular 
differentiation or mucin production, showing acinar, 
papillary, bronchioloalveolar or solid with mucin growth 
patterns or a mixture of these patterns [Travis et al, 
2015; Travis et al, 2011] with different classification for 
resected tumors. The lesion is, in general, peripheral and 
of smaller size compared to other subtypes. It accounts 
for about 50% of NSCLC cases [Chen et al, 2014]. 
SQCC originates predominantly in proximal airways and is 
more strongly associated with smoking and chronic 
inflammation than ADC. It is characterized by 
keratinization that may take the form of squamous pearls 
or by individual cells with markedly eosinophilic dense 
cytoplasm [Chen et al, 2014; Travis et al, 2015]. It 
accounts for about 40% of all NSCLCs [Chen et al, 2014]. 
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LCC is the less frequent tumor histotype among NSCLCs 
and it is diagnosed after ruling out the presence of cells or 
biomarkers characteristic of ADC, SQCC or SCLC. LCC is 
an undifferentiated NSCLC that lacks the cytological and 
architectural features of small cell carcinoma and 
glandular or squamous differentiation. Its cells typically 
have large nuclei, prominent nucleoli and a moderate 




Lung cancer circulating biomarkers 
 
Biomarkers are defined as molecules that can discriminate 
between a specific condition and normal status. Cancer 
biomarkers are biomolecules of various nature (proteins, 
genetic material, oligosaccharides, lipids, metabolites) 
that can be used for different medical purposes: 
diagnosis, prediction/staging, prognosis, treatment  [I and 
Cho, 2015]. 
Determining the expression of a lung cancer biomarker in 
body fluids can be a convenient and non-invasive method 
for screening and diagnosis of a certain disease. 
Currently, selected serum biomarkers are used in clinical 
practice as ancillary methods for lung cancer detection but 
their clinical utility is hampered by limited sensitivity 
and/or specificity. Examples of commonly available lung 
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cancer biomarkers are: Cytokeratin 19 Fragment (CYFRA 
21-1) [Schneider et al, 2000; Xu et al, 2015], 
Carcinoembryonic Antigen (CEA) [Schneider et al, 2000; 
Wang XB et al, 2014], Squamous Cell Carcinoma Antigen 
(SCC-Ag) [Schneider et al, 2000; Yu et al, 2013], Neuron-
Specific Enolase (NSE) [Schneider et al, 2000; Wang B et 
al, 2014], Progastrin-Releasing Peptide (ProGRP) [Kim et 
al, 2011] and Epidermal Growth Factor Receptor (EGFR) 
[Romero-Ventosa et al, 2015]. 
CYFRA 21-1 is a cytokeratin 19 fragment found in 
epithelial and bronchial tree cancer and it is typically 
associated with SQCC. 
CEA is an oncofetal protein normally produced in the 
gastrointestinal tissue during fetal development but not 
expressed in adult tissues. The levels of this protein in 
lung cancer are elevated and inversely correlated with 
response to cancer therapy.  
SCC-Ag is a cytoplasmic structural protein that is elevated 
in NSCLC patients, particularly in patients whose tumors 
have high metastatic potential. 
NSE is an isoenzyme of the glycolytic enzyme enolase that 
is present in cells with neuroendocrine differentiation. 
Indeed, its levels are frequently increased in SQCLC 
patients. 
ProGRP is a precursor of GRP, which is produced by the 
neuroendocrine cells of SCLC; for this reason, its levels 
are higher in SCLC than in NSCLC. 
	 19	
Finally, EGFR mutations can be used as markers to predict 
the efficacy of treatments targeting EGFR. Mutations in 
the EGFR gene are routinely tested to identify patients 
who can benefit from treatment with tyrosine kinase 
inhibitors. 
However, the cited biomarkers are not specific for the 
diagnosis of lung cancer; their altered levels only suggest 





MicroRNAs (miRNAs) are endogenous, 19-24 nucleotides 
long, non-coding, single-stranded, RNA molecules. They 
mediate post-transcriptional gene silencing by inducing 
mRNA degradation or by suppressing translation initiation 
[Garzon et al, 2010; Krol et al, 2010]. MiRNA genes are 
transcribed into primary transcripts (pri-miRNA) by RNA 
polymerase II [Lee et al, 2004], or, in some cases, by 
RNA polymerase III [Borchert et al, 2006]. Pri-miRNA are 
processed by the RNase III enzyme Drosha to form a 
miRNA precursor (pre-miRNA) and then pre-miRNA are 
transported in the cytosol and processed by another 
RNase (Dicer) to form a mature miRNA. Mature miRNAs 
are incorporated into RNA-induced silencing complex 
(RISC) that can regulate the gene expression through 
different mecchanisms (Fig. 1). 
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Several studies demonstrated that miRNA targeting genes 
involved in cell cycle progression and differentiation are 
often down-regulated within tumor cells, while others, 
regulating the expression of genes involved in cell cycle 
progression and resistance to apoptosis, are up-regulated 
[Iorio et al, 2012 (a)]. MiRNAs are also present in blood 
and other biofluids. Circulating miRNAs are either stored 
in microparticles (exosomes, microvesicles and apoptotic 
bodies) [Zernecke et al, 2009; Valadi et al, 2007] or are 
associated with RNA-binding proteins [Arroyo et al, 2011] 
or lipoproteins [Vickers et al, 2011] that prevent their 
degradation. The abundance and variety of circulating 
miRNAs suggest a role in cell-cell communication [Zhang 
et al, 2010]. Circulating cell-free miRNAs have been 
proposed as a promising class of biomarkers due to their 
stability in biofluids; because miRNA levels are often 
altered in various diseases, including cancer, a potential 
application of miRNAs in disease diagnosis and prognosis 
has been proposed. [Esquela-Kerscher et al, 2006; 
Lujambio and Lowe, 2012; Iorio et al, 2012 (b); Negrini et 




Figure 1. MiRNA biogenesis and mechanism of function. 
(Modified from Winter et al, 2009). 
 
 
MiRNAs role in lung cancer 
 
MiRNA loci map to genomic regions commonly amplified or 
deleted in human cancers [Gaur et al, 2007]. 
Furthermore, miRNAs control several biological processes 
including cell proliferation, apoptosis and differentiation 
[Calin and Croce, 2006]. 
Uncontrolled proliferation is a crucial step in cancer 
progression and, for example, it has been shown that 
miR-192 overexpression in NSCLC cell lines A549 and 
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H460 inhibits cell proliferation and carcinogenesis in vivo 
[Feng et al, 2011]. Importantly, miRNAs play a different 
role depending on the cellular context; indeed miR-34a 
has been correlated to prostate cancer inhibition [Liu et al, 
2011], but it did not influence SCLC cells [Lee et al, 
2011]. 
Defects in programmed cell death (apoptosis) are an 
important causal factor of development and progression of 
cancer. There are two apoptosis activation mechanisms: 
the extrinsic pathway and the intrinsic pathway (also 
called the mitochondrial pathway). The extrinsic pathway 
is mediated by death receptors that are activated after 
binding ligands. TNF-α is one of these ligands and it is 
target for miR-19a overexpressed in different tumors, 
including lung cancer [Liu et al, 2011]. The intrinsic 
pathway is characterized by release of cytochrome c from 
the mitochondrial intermembrane space into the cytosol. 
There are miRNAs that regulate pro- or antiapoptotic 
protein (Bcl-2 proteins family); for example, miR-503 
decreases antiapoptotic Bcl-2 protein in NSCLC A549 cells 
[Qiu et al, 2013]. MiRNAs can also affect expression and 
activation of effector caspases; for example, miR-1 in 
A549 cells enhances activation of caspase-3 and 7 [Nasser 
et al, 2008]. 
During tumor growth, the center of the mass tends to be 
hypoperfused, and the reduction in oxygen levels 
reduction promotes angiogenesis. Let-7b and miR-126 
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levels are decreased in lung tumor tissue, and an 
antiangiogenic role in lung cancer has been proposed for 
these miRNAs [Jusufovic et al, 2012]; overexpression of 
miR-16 has been shown in vitro to reduce the ability of 
endothelial cells to form blood vessels [Chamorro-
Jorganes et al, 2011]. 
 
 
MiRNAs as biomarkers of lung cancer 
 
Several studies have reported that miRNAs are aberrantly 
expressed in circulating blood, leading to consider them as 
potential biomarkers [Ono et al, 2015; Ulivi et al, 2014]. 
Unfortunately the results of these studies are highly 
discordant and there is no overlap in the miRNA profiles 
proposed by various authors for the diagnosis of early 
lung cancer, even in studies using similar biological 
material [Ono et al, 2015; Ulivi et al, 2014]. 
Despite promising initial results, miRNA profiling of lung 
cancer proved to be more challenging than expected, as 
many pre- and post-analytical variables heavily impact on 
the findings. Thus, the discrepancy in results published in 
different studies may be attributable to: 
- differences in sample material preparation and in 
the methodology applied for miRNA determination 
(microarray, RT-qPCR, droplet digital-PCR) [Ono et 
al, 2015]; 
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- differences in human populations investigated  
(prevalence of Chinese studies compared to studies 
in  western countries); 
- differences in patient cohorts (lung cancer stage 
distribution) [Gyoba et al, 2016; Ulivi et al, 2014]; 
- small sample size [Gyoba et al, 2016; Ulivi et al, 
2014]. 
 
The use of circulating, cell-free, miRNAs as biomarkers for 
early diagnosis of lung cancer may reasonably be 
proposed under three conditions: 1) an accurate and 
reproducible method for miRNA quantification is available; 
2) the biomarkers are detectable in the specified sample 
material in the early stage of the disease; 3) the proposed 







































The aims of this PhD thesis are: 
 
1) to find a reliable method for quantification  of serum 
levels of selected miRNAs of interest for human lung 
cancer. For this purpose three different techniques 
of miRNA measurement were compared: relative 
qPCR, absolute qPCR and droplet digital PCR 
(ddPCR). 
2) to quantify and evaluate miRNAs of interest in a 
prospective study comparing miRNA levels in 
patients with early NSCLC and in controls (age-













































The initial approach to this study was the identification of 
a panel of miRNAs that may help discriminating lung 
cancer patients from smokers with no evidence of this 
disease. For this purpose, as a preliminary step, two 
systematic reviews of the pertinent miRNA literature were 
performed, the first on January 30, 2014 and the second 
on March 19, 2015, using the following search terms: 
diagnosis AND lung AND neoplasm [mesh] AND 
(circulating OR serum OR blood OR plasma) AND 
(microRNA* OR miR-*).  After completion of this literature 
review on miRNA aberrantly expressed in lung cancer 
patients’ biofluids, 10 miRNAs were initially chosen to be 
quantified in this study, based on high-quality papers 
reporting their potential use as biomarkers of lung cancer: 
hsa-miR-15b-5p [Boeri et al, 2011; Hennessy et al, 
2012], hsa-miR-21-5p [Boeri et al, 2011; Geng et al, 
2014; Hu et al, 2010; Le et al, 2012; Ma et al, 2013; 
Markou et al, 2013; Mozzoni et al, 2013; Qi et al, 2014; 
Shen et al, 2011 (a), Shen et al, 2011 (b); Tang et al, 
2013], hsa-miR-27b-3p [Hennessey et al, 2012], hsa-
miR-126-3p [Bianchi et al, 2011; Markou et al, 2013; 
Sanfiorenzo et al, 2013; Shen et al, 2011 (a)], hsa-miR-
155-5p [Heegard et al, 2012; Sanfiorenzo et al, 2013; 
Zheng et al, 2011], hsa-miR-210-3p [Boeri et al, 2011; 
Shen et al, 2011 (a), Shen et al, 2011 (b)], hsa-miR-
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221-3p [Boeri et al, 2011; Chen et al, 2012; Geng et al, 
2014; Heegard et al, 2012], hsa-miR-320a [Chen et al, 
2012; Sanfiorenzo et al, 2013], hsa-miR-486-5p 
[Bianchi et al, 2011; Boeri et al, 2011; Hu et al, 2010; 
Mozzoni et al, 2013; Shen et al, 2011 (a), Shen et al, 
2011 (b)], hsa-let-7a-5p [Bianchi et al, 2011; Hu et al, 




The study design developed in two parts: 
 
Part 1. Comparison of reproducibility and precision of 
methods for miRNA quantification. 
A methodological study was carried out to compare the 
reproducibility and precision of three different methods 
currently available for quantification of miRNAs in serum 
samples: 1) relative quantification by qPCR [Marabita et 
al, 2016]; 2) absolute quantification by qPCR [Hindson et 
al, 2013]; 3) absolute quantification by ddPCR [Hindson et 
al, 2013; Ferracin et al, 2015]. 
 
Part 2. Case-control study 
A case-control experiment was performed to compare the 
level of a panel of selected circulating miRNAs in patients 





The Varese University Hospital Ethics Committee approved 
this study (Protocol approval n. 37527). All participants 
were volunteers and provided informed consent to use 
their samples for research purposes. Research was carried 
out in compliance with the Helsinki Declaration. 
 
 
Samples and miRNAs used in this study 
	
Peripheral blood samples (5 mL) were obtained by 
venipuncture from 168 volunteer adult subjects: 85 
therapy-naïve patients with early NSCLC (stage I and II) 
[Rami-Porta et al, 2009] of both genders (mean age, 
68±9 SD years; male/female ratio 3.3:1), and 83 controls 
(asymptomatic smokers undergoing check-up evaluation; 
mean age, 62±6.8 SD years; male/female ratio 2.3:1). 
The samples, both patients and controls, were collected 
between 2014 and 2016. Sample size calculation [MedCalc 
Statistical Software V.13.3.3 (MedCalc Software bvba, 
Ostend, Belgium)] was based on our preliminary 
experiments of measurements of serum levels of let-7a 
and miR-21, that are among the most frequently 
measured miRNAs. Accordingly, a sample size of at least 
63 lung cancers and 63 controls was calculated as being 
required, based on α-error of 0.05, a power of 80% and 
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considering a difference of 15 copies/uL between mean 
values of lung cancer cases and controls to be relevant 
[assuming standard deviation of 30 copies/uL (twice the 
difference between mean values of lung cancer cases and 
controls)]. The planned sample size of 63 lung cancers 
and 63 controls was cautiously increased to 85 lung cases 
and 83 controls, considering possible errors and 
underestimated intra-group variability. 
 
 
Serum preparation and RNA extraction 
	
Peripheral blood was collected using sterile tubes without 
anticoagulant, with clot activator and gel for serum 
separation (BD Vacutainer®, Milan, Italy), and left at 
room temperature (R.T.) to coagulate, from a minimum of 
30 to a maximum of 60 minutes; then serum was 
separated by centrifugation at 800 g for 8 min at R.T. 
Serum was divided in 500 µL aliquots and stored at -80°C 
until further processing.  
Purification of total RNA, including miRNAs, was performed 
using the miRNeasy serum/plasma kit (Qiagen, Milan, 
Italy), starting from 200 µL of serum and following 
manufacturer’s instructions. One µg of MS2 phage carrier 
RNA (Roche, Monza, Italy) and 1 µL of a mix of UniSp2, 
UniSp4 and UniSp5 spike-ins (Exiqon, Euroclone, Milan, 
Italy) were added in the Qiazol reagent just before the 
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purification process, to assess the efficiency of RNA 
purification and the presence of possible PCR inhibitors. 
RNA was eluted from the column with 14 µL of nuclease-
free water and stored at -80°C. As the low amounts of 
RNA extracted from serum samples make the 
measurement of RNA concentrations to be used for 
retrotranscription and quantification of specific miRNAs 
unreliable, we conducted our analysis working with 
constant volumes for the whole procedure (blood, serum, 





Two µL of RNA extracted from each sample was reverse 
transcribed into cDNA in 10 µL total reaction, using the 
Universal cDNA synthesis kit II, part of the miRCURY 
LNA™ Universal RT microRNA PCR system (Exiqon, 
Euroclone, Milan, Italy), according to the manufacturer’s 
instructions. When assembling the reactions, 0.5 µL of 
UniSp6 and cel-miR-39-3p spike-ins were added for 
subsequent evaluation of efficiency of the reverse 
transcription step. Four µL of the cDNA were prediluted 4-
fold and stored at -20°C until use. 
The quality of extraction and retrotranscription were 





The four-fold diluted cDNAs were diluted a further 10 fold 
and 4 µL were used in each 10 µL qPCR reaction, 
completed with the addition of 6 µL of reaction mixture, 
composed of 1 µL of the specific miRCURY LNA PCR primer 
set and 5 µL of ExiLENT SYBR Green master mix (both 
from Exiqon-Euroclone, Milan, Italy). All reactions were 
performed in triplicate. A CFX96 realtime PCR instrument 
(Biorad, Milan, Italy) was used, following the 
manufacturer’s instructions for cycling conditions [95 °C 
for 10 min, followed by 40 cycles of 95 °C for 10 s and 
60°C for 1 min (1.6 °C/s ramp rate)]. 
 
 
Evaluation of hemolysis 
	
The samples were checked for the risk of hemolysis, a 
process that is known to affect determination of specific 
miRNAs [Pritchard et al, 2012 (b)]. As indicated by the 
Exiqon guidelines, we calculated the difference between 
the Cq values of hsa-miR-23a-3p and hsa-miR-451a, 
where hsa-miR-451a is a miRNA highly expressed in red 
blood cells whereas hsa-miR-23a-3p is a free miRNA 
unaffected by hemolysis [Exiqon guidelines: Profiling of 
microRNA in serum/plasma and other biofluids]. Samples 
were considered at risk of hemolysis when their ΔCq (miR-
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23a - miR-451a) was > 5 and in this case they were not 
included in analysis. 
 
 
Relative quantification of miRNAs by RT-qPCR 
	
Throughout this study the “sample maximization 
approach” was used, that is the analysis of few miRNAs 
and several samples at a time. Each plate included a “no 
template control” (NTC) for each mix and an interplate 
calibrator (IPC). The latter was used to correct Cq values 
for inter-run variations [𝐶𝑞𝑛𝑜𝑟𝑚 = 𝐶𝑞𝐺𝑂𝐼 −  !
!
 ( 𝐶𝑞𝐼𝑃𝐶𝑗 −!!!!
 !
!
 𝐶𝑞𝐼𝑃𝐶𝑖)!!!! ] where GOI is the gene of interest, m is the 
number of interplate calibrators in run “m”, and n is the 
total number of interplate calibrators [Exiqon guidelines: 
Profiling of microRNA in serum/plasma and other 
biofluids]. Data normalization for miRNA analysis should 
be performed using endogenous reference miRNAs, whose 
levels are not affected by the samples and conditions. 
However, while this is easily performed when analyzing 
intracellular miRNAs, it is more difficult in the case of 
serum samples, as circulating miRNAs likely derive from 
several, heterogeneous sources and there is a lack 
validated and reliable reference miRNA.  
In preliminary experiments we attempted to normalize the 
data using the Cqs of three putative endogenous 
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reference miRNAs (hsa-miR-103a-3p, hsa-miR-423-5p, 
hsa-miR-191-5p). Unfortunately, these miRNAs turned out 
to be well expressed yet quite variable from sample to 
sample. Therefore, the normalization was performed using 
the UniSp5 spike-in and values were expressed as 2^-
DCq (Cq miRNA of interest, corrected for IPC – Cq UniSp5, 
corrected for IPC). 
 
 
Standard curve construction and miRNAs absolute 
quantification with RT-qPCR 
	
For the purpose of standard curve construction, three 
unmodified oligoribonucleotides corresponding to hsa-
miR-21-5p (UAGCUUAUCAGACUGAUGUUGA), hsa-miR-
126-3p (UCGUACCGUGAGUAAUAAUGCG) and hsa-let-7a-
5p (UGAGGUAGUAGGUUGUAUAGUU) were synthesized 
and provided by Eurofins Genomics (Milan, Italy). 
Different dilutions of oligoribonucleotides in RNase-free 
water were prepared and the appropriate dilution (6 x 104 
copies) was reverse transcribed to cDNA in 10 µL total 
reaction, using the Universal cDNA synthesis kit II, as part 
of the miRCURY LNA™ Universal RT microRNA PCR system 
(Exiqon, Euroclone, Milan, Italy). A two-fold dilution series 
over nine points were prepared from the cDNA, starting 
from a dilution at 2000 copies/µL, then the nine dilutions 
were used as templates for qPCR. Each point was 
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performed in triplicate. The standard curve was 
constructed by plotting Cq values against the logarithmic 
concentration of the calibrator oligoribonucleotides. The 
amount of an unknown sample was quantified by 
interpolating the Cq values in the standard curve.  
 
 
MiRNA absolute quantification by ddPCR 
	
The ddPCR method was applied using the QX200™ Droplet 
Digital™ PCR System (Biorad, Milan, Italy), as described 
in detail by Campomenosi et al. [Campomenosi et al, 
2016]. 
The four-fold diluted cDNAs were diluted further 10 fold 
and were used in each ddPCR reaction, adding the desired 
miRCURY LNA PCR primer set at the appropriate dilution 
(experimentally determined by testing two different 
volumes of cDNAs and primers) (Table 1), 10 µL of QX200 
EvaGreen ddPCR Supermix (Biorad, Milan, Italy) and 
nuclease-free water up to 20 µL. Each 20 µl ddPCR 
reaction was loaded into an 8-channel droplet generation 
cartridge (Biorad, Milan, Italy); 70 µL of QX200 Droplet 
generation oil (Biorad, Milan, Italy) were added into the 
appropriate wells and the cartridge was loaded in the 
QX200™ Droplet Generator (Biorad, Milan, Italy) to 
generate the emulsion. The resulting droplets were 
transferred to a 96-well plate (Eppendorf) with a Rainin 
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multichannel pipette, the plate sealed with Pierceable foil 
(Biorad, Milan, Italy) and amplified by standard PCR using 
a T100TM Thermal Cycler (Biorad, Milan, Italy). Cycling 
conditions were: 95°C for 5 min, followed by 40 cycles of 
95°C for 30 s and 60°C for 1 min, followed by signal 
stabilization steps (4°C for 5 min, 90°C for 5 min) and 
final hold at 4°C. The ramp rate was 2°C/s. After PCR, 
plates were loaded into QX200™ Droplet Reader (Biorad, 
Milan, Italy) for detection. 
 
Table 1. Conditions for ddPCR 
Candidate miRNAs 
under study 
Primer volume cDNA volume 
hsa-miR-15b-5p 1 µL 2.5 µL 
hsa-miR-21-5p 1 µL 2.5 µL 
hsa-miR-27b-3p 1 µL 2.5 µL 
hsa-miR-126-3p  1 µL 2.5 µL 
hsa-miR155-5p 1 µL 5 µL 
hsa-miR-210-3p 0.5 µL 5 µL 
hsa-miR-221-3p 0.5 µL 2.5 µL 
hsa-miR-320a 0.5 µL 2.5 µL 
hsa-miR-486-5p  1 µL 5 µL 






Correlation between the qPCR (absolute and relative) and 
the ddPCR output analyses was tested by linear regression 
model. The precision of miRNA measurements was 
estimated with the Coefficient of Variation 
[CV=(SD/mean)*100] of quadruplicate measures for each 
sample, for both qPCR (each point was the mean of three 
technical replicates) and ddPCR. The CVs of the two 
assays were compared by t-test for paired data. 
Differences between control and lung cancer patients were 
tested by Mann-Whitney test, the Receiver Operating 
Characteristic (ROC) curve was constructed and the Area 
Under the Curve (AUC) calculated. A p value <0.05 was 
considered statistically significant. Data were analyzed 
with SPSS 10.6 software (Illinois, USA). 
 
 
Reproducibility and precision of miRNA assays by 
ddPCR 
	
We performed a panel of experiments to verify the 
reproducibility and precision of miRNA measurements 
performed by ddPCR. In particular, we tested:  
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- reproducibility of assay, starting from RNA 
(repeating retrotranscription) (four samples, six 
miRNAs); 
- reproducibility of assay, starting from the same 
cDNA (multiple freeze-thaw cycles) (eight samples, 
eight miRNAs); 
- precision of ddPCR replicate assays (ten samples, 

































To assess the reproducibility and precision of miRNA 
quantification approaches, two experiments were carried 
out. In the first (Fig. 2A), 15 serum samples (7 from 
patients; 8 from control individuals) were used to 
compare the precision of miRNA measurements performed 
with “relative” qPCR, “absolute” qPCR and droplet digital 
PCR (ddPCR), and to assess the correlation of 
measurements obtained with the three methods. In the 
second experiment (Fig. 2B) we investigated the 
correlation between the three methods of miRNA analysis 
in a larger number of samples (70 samples: 35 from 
patients, 35 from controls).  
For comparison of the different quantification methods 
listed above, we used three miRNAs that, according to the 
literature, are aberrantly expressed in lung cancer 
patients: hsa-miR-21-5p, hsa-miR-126-3p and hsa-let-7a-
5p [Campomenosi et al, 2016]. 
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Figure 2. Workflow of the experiments. 
A) In the first experiment, for determination of each miRNA of 
interest (miR-21, miR-126 and let-7a) in each of 15 serum 
samples, we performed 4 independent “relative” qPCRs, 4 
independent “absolute” qPCRs and 4 independent ddPCRs. B) In 
the second experiment, the miRNAs of interest were measured 
with “relative” qPCR, “absolute” qPCR and ddPCR in 70 serum 






Comparison between relative RT-qPCR and ddPCR 
	
In the first experiment (Fig. 2A), each of the four analyses 
in qPCR was done in triplicate, for a total of 180 
amplifications. We found that the trend of expression of 
miRNAs under study was similar with that found with 
ddPCR, as can be seen by comparative inspection of 
scatter plots in Fig. 3; however, the dispersion of the 
values was higher for qPCR. 
Indeed the precision, as measured by the Coefficient of 
Variation (CV), was significantly greater for ddPCR 
compared to qPCR when analyzing miR-21 (p=0.047), 
while there was no difference in precision between the two 
techniques for miR-126 (p=0.072) and let-7a (p=0.079) 
(Table 2). 
The correlation of qPCR and ddPCR values was statistically 
significant (Fig. 4). In detail, R-squared values were 0.980 
for miR-21, 0.983 for miR-126 and 0.978 for let-7a 
(p<0.0001 for all analyses). Notably, the time needed for 
a complete set of analyses was about 4-fold shorter with 




Figure 3. Scatter plots showing the distribution of expression of 
the selected miRNAs by 
“relative” qPCR (panels on the left) and ddPCR (panels on the 
right). For each of the fifteen samples 
the results of the four analyses is reported, together with the 
mean and standard deviation. (2^-DCq=(Cq miRNA of interest, 
corrected for IPC – Cq UniSp5, corrected for IPC)) 



















































































































































Table 2. Mean and standard deviation of Coefficients of 
Variation of miR-21, miR-126 and let-7a determinations with 
“relative” qPCR and ddPCR. 
 N 
Coefficient of Variation 
p* 
Mean Std. Deviation 
Pair 1 
 
miR-21 qPCR 15 12.129 5.827 
0.047 
miR-21 ddPCR 15 8.319 3.221 
Pair 2 
 
miR-126 qPCR 15 13.221 8.187 
0.072 
miR-126 ddPCR 15 7.948 4.859 
Pair 3 
 
let-7a qPCR 15 11.198 5.871 
0.079 
let-7a ddPCR 15 7.992 3.265 
* paired samples t-test 
 
 
Figure 4. Correlation analysis between “relative” qPCR and 
ddPCR data for the first experimental set, consisting of 15 
samples analyzed 4 times with each technique. 
 
In the second set of experiments (described in figure 2B) 
the correlation between the output data of the two 





























































methods (“relative” qPCR and ddPCR) was still significant 
(see fig. 5), although the R-squared were lower than in 
the previous set of experiments (Fig. 5). Indeed, R-
squared values were 0.536, 0.631 and 0.597 for miR-21, 
miR-126, let-7a, respectively. 
 
 
Figure 5. Correlation analysis between “relative” qPCR and 
ddPCR data for the second experimental set, consisting of 70 
samples analyzed with each technique. 
 
 
Comparison between absolute RT-qPCR and ddPCR 
	
As for the comparison between “relative” qPCR and 
ddPCR, we found that the trend of miRNAs expression was 
similar also when comparing “absolute” qPCR and ddPCR. 
Notably, for miR-126 and let-7a, the samples showed 
higher values in qPCR then in ddPCR: the estimated copy 
numbers in qPCR were approximately 2.4 and 3.9 fold 
greater, respectively, than in ddPCR (Fig. 6). 





























































Figure 6. Scatter plots showing the distribution of expression of 
the selected miRNAs by “absolute” qPCR (panels on the left) 
and ddPCR (panels on the right). For each of the fifteen 
samples the results of the four analyses is reported, together 
with the mean and standard deviation. 
(Modified from Campomenosi et al, 2016) 


















































































































































In the first experiment of comparison between “absolute” 
qPCR and ddPCR (Figure 2A), the precision of miRNA 
quantification, as measured by the CV, was significantly 
better for ddPCR compared to qPCR for let-7a (p=0.028), 
while it was not significantly different for miR-21 and miR-
126 (Table 3). 
 
Table 3. Mean and standard deviation of Coefficients of 
Variation of miR-21, miR-126 and let-7a determinations with 
“absolute” qPCR and ddPCR.  
(Modified from Campomenosi et al, 2016) 
 N 
Coefficient of Variation 
p* 
Mean Std. Deviation 
Pair 1 
 
miR-21 qPCR 15 11.040 5.4387 
0.123 
miR-21 ddPCR 15 8.319 3.2207 
Pair 2 
 
miR-126 qPCR 15 7.386 2.8837 
0.675 
miR-126 ddPCR 15 7.944 4.8446 
Pair 3 
 
let-7a qPCR 15 10.298 2.4077 
0.028 
let-7a ddPCR 15 7.992 3.2646 
* paired samples t-test 
 
Linear regression analysis indicated a significant 
correlation between “absolute” qPCR and ddPCR values 
(Fig. 7). R-squared values were 0.963 for miR-21, 0.984 
for miR-126 and 0.978 for let-7a (p<0.0001 for all 
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regressions). However, the slope (b) of the regression line 
for miR-126 (b=0.420 [CI95% 0.391-0.452]) and let-7a 
(b=0.2561 [CI95% 0.234-0.278]) was significantly lower 
than one, due to the lower number of copies measured by 
ddPCR as compared to what estimated with the external 
calibrator in qPCR.  
These systematic differences, characterized by higher 
values of “absolute” qPCR compare to ddPCR 
measurements of miRNAs will be addressed in the 
discussion of the thesis. 
 
 
Figure 7. Correlation analysis between “absolute” qPCR and 
ddPCR data for the first experimental set, consisting of 15 
samples analyzed 4 times with each technique. 
(Modified from Campomenosi et al, 2016) 
 
 
In the second experiment (Figure 2B), repeated on the 
cohort of 35 samples from patients and 35 from matched 
controls to compare “absolute” qPCR to ddPCR, again we 
found significant correlation between “absolute” qPCR and 






























































ddPCR values (R-squared=0.948 for miR-21, 0.954 for 
miR-126 and 0.949 for let-7a; p<0.0001 for all 
regressions) (Fig. 8). Consistently, the slopes for miR-126 
and let-7a were confirmed to be significantly lower than 1 
(b=0.695 [CI95% 0.658-0.731] and b=0.347 [CI95% 
0.328-0.366], respectively) (Fig. 8). 
 
 
Figure 8. Correlation analysis between “absolute” qPCR and 
ddPCR data for the second experimental set, consisting of 70 
samples analyzed with each technique. 
(Modified from Campomenosi et al, 2016) 
 
 
Refinement of miRNA panel based on sensitivity to 
hemolysis 
	
A good biomarker needs to be “robust” (i.e. it should not 
be influenced by confounding factors, one of which is 
hemolysis), when serum samples are used as starting 
material. Indeed, the levels of some miRNAs have been 
shown to change in the presence of hemolysis, as some 




























































miRNAs are released by lysed red blood cells [Pritchard et 
al, 2012 (b)]. Therefore, we decided to perform 
preliminary experiments aimed at identifying the 
sensitivity to hemolysis of the miRNAs selected. In this 
preliminary experiment, we found that among the 10 
miRNAs examined (hsa-miR-15b-5p, hsa-miR-21-5p, hsa-
miR-27b-3p, hsa-miR-126-3p, hsa-miR-155-5p, hsa-miR-
210-3p, hsa-miR-221-3p, hsa-miR-320a, hsa-miR-486-
5p, hsa-let-7a-5p) the level of miR-486 and miR-155 
significantly increased in presence of hemolysis. Notably, 
when the few hemolyzed samples were excluded from 
analysis, the levels of these two miRNAs were not 
different in the serum of NSCLC patients compared to 
controls. These observations led us to exclude miR-486 
and miR-155 as possible biomarkers of lung cancer (Fig. 
9). The remaining eight miRNAs underwent further 
analyses to identify those able to discriminate between 




Figure 9. Scatter plots showing the concentration of miR-486 
and miR-155 in controls (CTRL) and patients (NSCLC) 
considered globally (left panel), and either in absence (middle 
panel) or presence (right panel) of hemolysis. These miRNAs 
are influenced by hemolysis. 
 
 
Reproducibility of miRNAs analyses performed by 
ddPCR 
	
We performed various reproducibility tests. First, we 
tested miRNAs stability before and after multiple freeze-
thaw cycles of the cDNAs between the two measures (Fig. 
10). We analyzed eight samples and four miRNAs by 
ddPCR. We found a good correlation between the two 



































































































depended on the specific miRNA being analyzed, 




Figure 10. Correlation analysis between miRNA measures 
obtained from the same cDNAs before or after multiple freeze-
thaw cycles, for four miRNAs under study. Axis numbers 
indicate copies of the specific miRNA per microliter of ddPCR 
reaction. 
 
We also decided to test the correlation of the measures 
obtained from two independent retrotranscription 
reactions on four samples, tested with three miRNAs. The 
R-squared was about 0.9 for all miRNAs (Fig. 11). 
Finally, we aimed to test reproducibility of two ddPCR 
reactions performed on the same ten samples, with eight 



































































miRNAs. The R-squared values ranged from 0.9068 for 
miR-320a to 0.9970 for miR-126 (Fig. 12). 
 
 
Figure 11. Regression lines showing the correlation between 
measures obtained on the same RNAs after two independent 
retrotranscriptions followed by ddPCR analysis, for three of the 
miRNAs under study. 
 

















































Figure 12. Correlation analysis between two ddPCR replicates 
performed on ten samples and eight miRNAs. 
 
 

































































































































In summary, from Part 1 of this study we can conclude 
that ddPCR appears to be the most robust of the three 
techniques tested (“relative” qPCR, “absolute” qPCR, 
ddPCR), in terms of reproducibility, precision and 
throughput.  
Therefore, ddPCR was the technique chosen for our case-
control experiment in Part 2 of this study, to quantify the 
selected panel of miRNAs in serum samples.  
 
 
CASE-CONTROL EXPERIMENT (TRAINING SET) 
	
	
ddPCR analyses of serum miRNAs to identify 
putative biomarkers for screening of early lung 
cancer 
	
The panel of eight miRNAs selected based on our 
preliminary review of the literature, and after the 
refinement based on sensitivity to hemolysis (from the 10 
miRNAs initially considered, we excluded miR-486 and 
miR-155), was measured in our training set, composed of 
85 therapy-naïve patients with stage I and II NSCLC, of 
both genders, and 83 matched controls (see Materials and 
Methods on page 30). As illustrated in Fig. 13, four out of 
the eight tested miRNAs showed significant differences in 
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serum levels between lung cancer patients and controls: 
let-7a, miR-320a, miR-210 (p<0.0001) and miR-221 
(p=0.0119). For each of these four “predictive miRNAs”, 
the Receiver Operating Characteristic (ROC) curve was 
constructed and the Area Under the Curve (AUC) 
calculated (Fig. 14). AUC indicated fair accuracy in 
identifying early non-small cell lung cancer cases (0.745 
for miR-210; 0.730 for let-7a; 0.708 for miR-320a; 0.612 
for miR-221). By applying the cut-off values indicated in 
Table 5, we found a sensitivity of 75.3% for miR-210, 
70.6% for let-7a, 80% for miR-320a and 63.5% for miR-




Figure 13. Scatter plots showing the concentration (in copies/ 
µL) of the eight selected miRNAs in controls (CTRL) and in 
patients with stage I-II (NSCLC), evaluated by ddPCR 










































































































































Figure 14. Graphs showing ROC and AUC values for four 
putative miRNA biomarkers 
 
Table 4. AUC of the ROC curves, cut-off, sensitivity and 




Sensitivity % Specificity % 
miR-210 0.745 ≤3.6 75.3 (64.7-84) 64.6 (53.3-74.9) 
let-7a 0.730 ≤53.1 70.6 (59.7-80) 68.7 (57.6-78.4) 
miR-320a 0.708 ≤21.9 80 (69.9-87.9) 55.4 (44.1-66.3) 


















































































Lung cancer is the main cause of cancer-related mortality 
in the developed world and the identification of sensitive 
and specific biomarkers for lung cancer screening may 
lead to early diagnosis and thus improve survival rates. 
These biomarkers should be ideally measured using non-
invasive, reliable, widely available and low cost 
techniques. Circulating miRNAs are considered good 
candidates as lung cancer biomarkers [Markou et al, 
2013]. However, several methodological problems have 
been highlighted in the quantification of miRNAs in 
biofluids and currently there is no consensus on which 
method should be used (microarray; relative/absolute 
qPCR; ddPCR) to quantify circulating miRNAs [Ono et al, 
2015; Ferracin et al, 2015]. 
We compared the performance of three miRNA 
quantification methods: relative qPCR, absolute qPCR and 
ddPCR. 
Relative qPCR is the most commonly used method 
reported in the literature for quantification of circulating 
miRNAs, in spite of the lack of reliable endogenous 
reference miRNAs in biofluids [Le et al, 2012]. Indeed, in 
our preliminary experiments we tested miR-103a-3p, miR-
191-5p and miR-423-5p as endogenous reference 
miRNAs, as suggested by the Exiqon guidelines, but these 
miRNAs showed excessively high variability among 
samples, making their use as reference molecules 
unreliable. Therefore, we performed normalization of 
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relative qPCR results using the UniSp5 spike-in, a 
synthetic miRNA which is added by the operator at the 
beginning of RNA extraction, as suggested by several 
authors [Schwarzenbach et al, 2015; Roberts et al, 2014]. 
However, also UniSp5 spike-in is not exempt from 
criticisms, as this small molecule neither follows the 
endogenous miRNA processing nor is it complexed in the 
serum in the same way that endogenous miRNAs are. 
Overall it is generally agreed that normalization remains a 
major weakness of the relative qPCR technique, 
regardless of the molecule used for normalization 
[Marabita et al, 2016]. On the other hand, the absolute 
qPCR method estimates the number of target copies in 
unknown samples based on their fluorescence compared 
to that of a standard calibrator. Therefore, absolute qPCR 
depends on accurate quantification, dilution and 
downstream processing of the calibrator itself. In 
constructing the calibrator, errors are possible at several 
levels, including errouneous estimation of the initial 
concentration, suboptimal efficiency of retrotranscription 
[Bustin et al, 2015] that may contribute to erroneous 
quantification and low reproducibility of the calibration 
curve in different experiments. These problems, and the 
fact that efficiency in PCR amplification of synthetic 
standards may differ from that of complex samples, 
represent the major weaknesses of quantification by 
absolute qPCR [Lai et al, 2005]. 
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In the ddPCR technique, PCR-positive and PCR-negative 
droplets are counted to directly provide absolute 
quantification of the target DNA in digital form [Hindson et 
al, 2011]. The output of the analyses is given in copies 
per microliter of reaction, with 95% confidence intervals. 
Thus, the ddPCR system allows measurement of miRNA 
expression levels with remarkable precision, averting the 
need for technical replicates [Hindson et al, 2011], 
because the sample is partitioned into thousands of micro-
reactions. This, in turn, accelerates the quantification 
process, as more samples, or a higher number of targets, 
can be analyzed on a single 96-multiwell plate. 
Furthermore, reagents for quantification based on DNA 
binding dyes, like EvaGreen, have shown results 
comparable to hydrolysis probes in ddPCR when applied to 
the quantification of circulating miRNAs [Miotto et al, 
2014].  
In the present study, the results of miRNAs analyses with 
the different techniques significantly correlated. The 
correlation between relative qPCR and ddPCR suggests 
that the normalization by the UniSp5 spike-in is applicable 
to miRNA quantification whenever there is no availability 
of endogenous reference genes, such as in the serum. 
However, it is important to note that ddPCR showed less 
variability in replicate analyses than relative qPCR, in 
particular when four replicates of the same samples were 
analyzed with the two techniques (Fig. 3, 4 and Table 2). 
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When absolute qPCR and ddPCR were compared, the 
correlation was again significant. In this case, the 
correlation was similar either when comparison was made 
with four replicate analyses of the same samples (Fig. 6, 7 
and Table 3) or with a larger number of sera (Fig. 8). 
However, we observed that for two of three miRNAs (miR-
126 and let-7a), the ddPCR methods yielded 
approximately 2.4 and 3.9 fold lower values than absolute 
qPCR, respectively. We confirmed these systematic 
differences between absolute ddPCR and qPCR 
measurements in a separate experiment: we quantified by 
ddPCR the cDNAs of the specific calibrators used to build 
the calibration curves for qPCR and consistently found a 
lower concentration than the theoretical one used for 
calculations in qPCR. This systematic difference is further 
confirmed by lower levels of the miRNA measurements 
obtained by the absolute qPCR method, compared with 
those obtained by ddPCR, reported by other authors 
[Hindson et al, 2013]. It is likely that such discrepancy is 
due to sub-optimal efficiency of retrotranscription and/or 
amplification of standard template, leading to a defect in 
calibration curve construction.  
The fact that ddPCR does not require a reference or a 
calibrator for quantification, represents one of the main 
advantages of this method. However, to make the results 
on the miRNAs more reliable we recently decided to 
introduce, for future analyses, a “normalization” step with 
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UniSp4. UniSp4 is one of the spike-ins introduced in 
serum samples right before extraction, thus it is present 
at all the different stages of the experiment. We 
calculated a corrective factor that takes into consideration 
the copies of UniSp4 introduced and the copies of UniSp4 
detected by ddPCR. In this way the levels of the miRNAs 
of interest will be corrected by taking into consideration 
this correction factor, making the analysis more robust. 
The other strong point of ddPCR is that it is an end-point 
analysis; absolute quantification is based on the presence 
or absence of fluorescence in each droplet rather than on 
fluorescence levels during the reaction, making it less 
sensitive to the presence of potential PCR inhibitors [Rački 
et al, 2014]. 
Our results suggest that for the purpose of miRNA 
measurement in biofluids the ddPCR method is more 
robust compared to relative or absolute qPCR, with the 
important advantage of providing absolute quantification 
without the need to use calibrators and standard curves, 
also providing a higher throughput at a similar cost-per-
reaction. The time needed to complete a set of analyses, 
including post-PCR processing data, was about 4-fold 
shorter with ddPCR than with relative qPCR and 2-fold 
shorter than with absolute qPCR. In our laboratory the 
estimated cost of the amplification step, for each miRNA 
determination in serum was about 3.33 € for qPCR 
(performed in triplicate) and about 3.66 € for ddPCR. 
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For these reasons we decided to use ddPCR as the 
technique of choice for quantification of circulating 
miRNAs as putative biomarkers of lung cancer.  
 
The second part of the present work consisted of a case-
control study in a cohort of 85 patients with stage I-II 
NSCLC and 83 controls. This cohort was used as training 
set for assessing the diagnostic accuracy of eight miRNAs 
(hsa-miR-15b-5p, hsa-miR-21-5p, hsa-miR-27b-3p, hsa-
miR-126-3p, hsa-miR-210-3p, hsa-miR-221-3p, hsa-miR-
320a, hsa-let-7a-5p) reported in the literature to be 
aberrantly expressed in the serum of patients, using the 
ddPCR technique [Ferracin et al, 2015]. 
 
Four out of eight miRNAs that we investigated showed 
significant differences between NSCLC cases and controls, 
namely let-7a, miR-320a, miR-210  (p<0.0001) and miR-
221 (p=0.0119) (Fig. 13). 
These findings are only partially concordant with the 
literature. While alterations in the levels of miR-21 are 
frequently reported in the serum of lung cancer patients 
(mainly with advanced stage disease) [Geng et al, 2014; 
Qi et al, 2014; Ma J et al, 2013; Markou et al, 2013; Le et 
al, 2012; Shen et al, 2011 (a); Shen et al, 2011 (b); Tang 
et al 2013], in our training set miR-21 levels were not 
affected in samples from early stage NSCLC patients as 
compared to controls. However, there are two 
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considerations to make: first, our cohort was exclusively 
composed of early-stage patients (stage I and II), therapy 
naïve, while the previously mentioned studies included 
mainly patients with advanced lung cancer. Moreover, 
most of these published works were performed in oriental 
populations (Chinese cohorts). At present, no data are 
available on differences in miRNA expression based on 
ethnic origins, but this potential explanation for the 
different results obtained in our study cannot be ruled out. 
In another independent Italian lung cancer patient cohort, 
no evidence of increase miR-21 levels was found [Ferracin 
et al, 2015] similar to our study. 
We found decreased levels of miR-126 and let-7a in lung 
cancer patients compared to controls, in agreement with 
the literature [Bianchi et al, 2011; Sanfiorenzo et al, 
2013; Markou et al, 2013; Shen et al, 2011 (a); Jeong et 
al, 2011; Heegard et al, 2012; Kang et al 2013]. These 
miRNAs have been described to possess oncosuppressive 
activity and their levels are decreased in lung tumors 
compared to normal tissues. MiR-126 has been shown to 
target molecules with a potential role in blood-vessel 
formation such as VEGFA, VCAM1, EGFL7 and PIK3R 
[Jusufovic et al, 2012; Zhu et al, 2011; Harris et al, 2008; 
Guo et al 2008], while the let-7 family targets the 
expression of proteins involved in lung cancer 
development like MYC and K-RAS [Johnson et al 2005; 
Kim et al 2009]. The decrease in let-7a serum levels in 
	 68	
lung cancer patients in our study was significant, 
suggesting a potential application of this miRNA as a 
biomarker for early NSCLC.   
Although miR-221 was one of the miRNAs selected 
because its levels are altered in presence of lung cancer, 
there is no agreement on the direction of variation: Chen 
reported an increase in miR-221 in sera of lung cancer 
patients, whereas Heegard found a decrease of the same 
miRNA, in keeping with our results [Chen et al, 2012; 
Heegard et al, 2012]. The decrease in miR-221 is in 
agreement with its proposed role as an anti-angiogenic 
miRNA [Kuehbacher et al, 2008; Urbich et al, 2008]. 
Again, comparison of cohorts with different ethnicity 
would help to understand if this might be a possible 
explanation. 
According to the literature, miR-320a and miR-210 appear 
to be up-regulated in the serum of lung cancer bearing 
patients, compared to control subjects [Chen et al, 2012; 
Shen et al, 2011 (a); Shen et al, 2011 (b)]. However, we 
found a significant down-regulation of these miRNAs. 
Again, published work refers mainly to Chinese cohorts. 
Some of the published studies rely on the ratio or on the 
difference between two different miRNAs, rather than on 
increase or decrease of specific miRNAs to predict tumor 
risk. For example, Hennessey et al. described that the 
difference between miR-15b and miR-27b could be used 
as an indicator to discriminate NSCLC from healthy 
	 69	
controls [Hennessey et al, 2012]. Boeri et al found a 
signature of 16 miRNA ratios, discriminating between 
cancer patients and healthy controls, among which miR-
15b was present as a ratio with miR-92a (miR-15b/miR-
92a) [Boeri et al, 2011]. In our case we found a negligible 
variation of miR-15b and miR-27b serum level in lung 
cancer patients compared to controls. 
For each of the four miRNAs (let-7a, miR-210, miR-320a 
and miR-221), for which we found significant differences 
in serum levels between lung cancer patients and controls, 
the ROC curve was constructed and the AUC calculated. 
These showed fair accuracy in identifying early lung 
cancer cases (about 0.7 for each of the four miRNA) (Fig. 
14), suggesting their potential role as biomarkers of lung 
cancer. 
 
In conclusion, ddPCR proved to be a robust method for 
absolute quantification of miRNA serum levels in patients 
with early NSCLC. The ddPCR approach has advantages, 
as it averts the search of a stable reference miRNA and it 
does not need construction of calibrator curve for the 
analysis. Also the miRCURY LNA assay (Exiqon) provided a 
greater specificity compared to other miRNA expression 
platforms [Mestdagh et al, 2014]. A major benefit is that 
it has a universal cDNA system so we can quantify any 
miRNA without making miRNA-specific reverse 
transcription [Miotto et al, 2014]. 
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These results, obtained in the training set, need to be 
validated both internally and externally, to assess whether 
a combination of four miRNAs (let-7a, miR-210, miR-320a 
and miR-221) and possibly additional miRNAs may identify 
subjects who need further investigation for the presence 
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